Medical Therapy. Efficacy or Lack of Efficacy

Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide

Liezl T. Domingo, D. Dunbar Ivy, Steven H. Abman, Alicia M. Grenolds, James T. MacLean, J. A. Breaux, Katie J. Minford, Benjamin S. FrankUniversity of Utah. University of Colorado.United States Frontiers in PediatricsFront Pediatr 2022; 10: DOI: 10.3389/fped.2022.1014922 AbstractIntroduction: Riociguat, an oral soluble guanylate cyclase stimulator, has been approved for use in adults with pulmonary arterial hypertension […]

Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide Read More »

High-dose epoprostenol therapy in pediatric patients with pulmonary hypertension and developmental lung disease: A report of two cases

Yoshie Fukusawa, Hidenori Yamamoto, Miharu Ito, Akiko Saito, Kiyotaka Go, Yoshihito Morimoto, Kazushi Yasuda, Yoshiaki Sato, Masahiro Hayakawa, Taichi KatoNagoya University and Nagoya University Hospital. Ogaki Municipal Hospital. Japanese Red Cross Nagoya Daichi Hospital. Aichi Child Health and Medical General Center.Japan Frontiers in Pediatrics. Pediatric Cardiology SectionFront Pediatr 2023; 11: DOI: 10.3389/fped.2023.1116434 AbstractPulmonary hypertension (PH) with

High-dose epoprostenol therapy in pediatric patients with pulmonary hypertension and developmental lung disease: A report of two cases Read More »

Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension

Elizabeth Colglazier, Leah Stevens, Claire Parker, Hythem M. Nawaytou, Elena K. Amin, Jasmine Becerra, Martina Steurer, Jeffrey R. FinemanUniversity of California San FranciscoUnited States Pulmonary CirculationPulm Circ 2022; 12: DOI: 10.1002/pul2.12159 AbstractDespite the increase in therapeutic options, parenteral prostacyclins remain the cornerstone in the medical management of pulmonary arterial hypertension (PAH). While the use of parenteral

Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension Read More »

Systemic Sirolimus Therapy for Infants and Children With Pulmonary Vein Stenosis

Jay D. Patel, Michael Briones, Mansi Mandhani, Shannon Jones, Divya Suthar, Rosemary Gray, Joelle Pettus, Courtney McCraken, Amanda Thomas, Christopher J. PetitEmory University and Children’s Healthcare of AtlantaUnited States Journal of the American College of CardiologyJ Am Coll Cardiol 2021; 77: 2807-2818DOI: 10.1016/j.jacc.2021.04.013 AbstractBackground: Anatomic interventions for pulmonary vein stenosis (PVS) in infants and children have been

Systemic Sirolimus Therapy for Infants and Children With Pulmonary Vein Stenosis Read More »

International practice heterogeneity in pre-transplant management of pulmonary hypertension related to pediatric left heart disease

Rachel K. Hopper, Oscar van der Have, Seth A. Hollander, Anne I. Dipchand, Valeria Perez de Sa, Jeffery A. Feinstein, Karin Tran-LundmarkStanford University and Lucille Packard Children’s Hospital. Lund University. Skane University Hospital. University of Toronto and the Hospital for Sick ChildrenUnited States, Sweden and Canada Pediatric TransplantationPediatr Transplant 2023; DOI: 10.1111/petr.14461 AbstractBackground: Elevated pulmonary vascular resistance

International practice heterogeneity in pre-transplant management of pulmonary hypertension related to pediatric left heart disease Read More »

Scroll to Top